Prostate cancer (PCa) is a difficult disease to understand. The tumor's genetic diversity increases as mutations accumulate, resulting in distinct subclones. On the other hand, non-genetic intra-tumoral heterogeneity, the cellular differentiation state, and the interaction between subclonal evolution and transcriptional heterogeneity, on the other hand, are poorly understood. The authors performed single-cell RNA sequencing on 14 untreated PCa patients in this study. They developed a comprehensive cell atlas of PCa patients and mapped developmental states onto tumor subclonal evolution. They find distinct subclones in PCa patients and then divide tumor cells into four transcriptional subtypes: EMT-like (subtype 0), luminal A-like (subtype 1), luminal B/C-like (subtype 2), and basal-like (subtype 3). These subtypes are organized hierarchically into stem cell-like and differentiated states. Surprisingly, multiple subclones within a single primary tumor have distinct preferential subtype combinations. Furthermore, subclones exhibit varying levels of communication with other cell types within the tumor ecosystem, which may modulate the distinct transcriptional subtypes of the subclones. Notably, they discovered that tumor cell transcriptional heterogeneity and cellular ecosystem diversity correlate with features of a poor prognosis by integrating TCGA data. Their research examines subclonal and transcriptional heterogeneity and its implications for patient prognosis.
Clinical Applications of Genetic SequencersApril 4, 2023Genetic sequencer, also known as DNA sequencer, is an instrument used to determine the sequence, type, and quantity of nucleotides in a DNA fragment. It is mainly used in human genome sequencing, gene...view
Microbiome Sequencing: The Next Frontier in Personalized MedicineJune 26, 2023In the past few decades, we have witnessed remarkable advancements in medical technology that have revolutionized the way we approach healthcare. One of the most promising frontiers in this field is m...view
What Is The Nommal Metabolic Testing?March 11, 2024In the rapidly evolving landscape of healthcare diagnostics, metabolic testing has emerged as a cornerstone for understanding individual health profiles and tailoring interventions accordingly. Capita...view
What is In Vitro Diagnostic Reagents?April 4, 2023In vitro diagnostic reagents refer to in vitro diagnostic reagents managed by medical device management, including reagents, reagent kits, calibration products, quality control products, etc. used for...view
CapitalBio: Advancing Breast Cancer Research with Microarray ScannersFebruary 7, 2024Introduction to CapitalBio and BRCA Gene ResearchCapitalBio, a global leader in biotechnology, is making significant strides in breast cancer research with its advanced microarray scanners. These inst...view